David B. Roberts Sells 26,683 Shares of LeMaitre Vascular, Inc. (LMAT) Stock
LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider David B. Roberts sold 26,683 shares of LeMaitre Vascular stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $36.67, for a total value of $978,465.61. Following the sale, the insider now directly owns 48,108 shares of the company’s stock, valued at approximately $1,764,120.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
LeMaitre Vascular, Inc. (LMAT) opened at 36.60 on Friday. The firm has a market cap of $696.21 million, a PE ratio of 52.29 and a beta of 0.67. LeMaitre Vascular, Inc. has a one year low of $18.55 and a one year high of $37.50. The stock has a 50 day moving average price of $32.95 and a 200 day moving average price of $28.66.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.06. The firm had revenue of $25.80 million during the quarter, compared to the consensus estimate of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The firm’s revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.14 earnings per share. Equities research analysts expect that LeMaitre Vascular, Inc. will post $0.80 EPS for the current year.
LeMaitre Vascular declared that its Board of Directors has authorized a share buyback program on Thursday, July 27th that allows the company to buyback $7.50 million in shares. This buyback authorization allows the medical instruments supplier to purchase up to 1.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Wednesday, August 23rd will be given a dividend of $0.055 per share. The ex-dividend date of this dividend is Monday, August 21st. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.60%. LeMaitre Vascular’s payout ratio is 31.88%.
WARNING: “David B. Roberts Sells 26,683 Shares of LeMaitre Vascular, Inc. (LMAT) Stock” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/david-b-roberts-sells-26683-shares-of-lemaitre-vascular-inc-lmat-stock/1539310.html.
Several brokerages have recently issued reports on LMAT. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price objective (up previously from $29.00) on shares of LeMaitre Vascular in a report on Sunday, July 30th. Benchmark Co. raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, July 28th. BidaskClub cut LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Craig Hallum began coverage on LeMaitre Vascular in a report on Tuesday, June 6th. They issued a “hold” rating and a $31.00 price objective for the company. Finally, Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $30.17.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Columbia Wanger Asset Management LLC boosted its position in shares of LeMaitre Vascular by 21.0% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,093,903 shares of the medical instruments supplier’s stock worth $26,943,000 after buying an additional 189,608 shares during the period. Conestoga Capital Advisors LLC boosted its stake in LeMaitre Vascular by 45.8% in the second quarter. Conestoga Capital Advisors LLC now owns 565,069 shares of the medical instruments supplier’s stock valued at $17,641,000 after buying an additional 177,379 shares during the last quarter. Vanguard Group Inc. boosted its stake in LeMaitre Vascular by 23.5% in the second quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock valued at $25,462,000 after buying an additional 155,249 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in LeMaitre Vascular during the second quarter valued at approximately $4,661,000. Finally, Bank of New York Mellon Corp boosted its stake in LeMaitre Vascular by 137.9% in the second quarter. Bank of New York Mellon Corp now owns 210,628 shares of the medical instruments supplier’s stock valued at $6,574,000 after buying an additional 122,076 shares during the last quarter. 66.32% of the stock is owned by institutional investors and hedge funds.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.